These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16506589)

  • 1. [New antibiotics for treatment of MRSA infections. Comparison of treatment with vancomycin].
    Burkhardt O; Derendorf H; Welte T
    Med Monatsschr Pharm; 2006 Feb; 29(2):56-62; quiz 63-4. PubMed ID: 16506589
    [No Abstract]   [Full Text] [Related]  

  • 2. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
    Micek ST
    Clin Infect Dis; 2007 Sep; 45 Suppl 3():S184-90. PubMed ID: 17712745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
    Sakoulas G; Moellering RC
    Clin Infect Dis; 2008 Jun; 46 Suppl 5():S360-7. PubMed ID: 18462091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Key considerations in the treatment of complicated staphylococcal infections.
    Jones RN
    Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():3-9. PubMed ID: 18226084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of vancomycin for treatment of methicillin-resistant Staphylococcus aureus infections.
    Howden BP; Johnson PD; Charles PG; Grayson ML
    Clin Infect Dis; 2004 Nov; 39(10):1544; author reply 1544-5. PubMed ID: 15546096
    [No Abstract]   [Full Text] [Related]  

  • 6. Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes.
    Lodise TP; McKinnon PS
    Pharmacotherapy; 2007 Jul; 27(7):1001-12. PubMed ID: 17594206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of severe infections caused by Staphylococcus aureus: a change in the vancomycin paradigm?
    Aranha Camargo LF
    Shock; 2008 Oct; 30 Suppl 1():67-9. PubMed ID: 18704006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative agents for the treatment of invasive infections due to methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to vancomycin.
    Tattevin P; Arvieux C; Michelet C
    Arch Intern Med; 2007 Jun; 167(11):1206; author reply 1208-9. PubMed ID: 17563033
    [No Abstract]   [Full Text] [Related]  

  • 9. [The Dutch MRSA policy should be retained].
    Vlaminckx BJ; Troelstra A; van der Bruggen T
    Ned Tijdschr Geneeskd; 2006 Aug; 150(34):1884. PubMed ID: 16970011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of MRSA infections with older molecules: a reasonable option for investigation.
    Hmouda H; Ben Salem C; Bouraoui K; Jemni L
    Arch Intern Med; 2007 Jun; 167(11):1207-8; author reply 1208-9. PubMed ID: 17563034
    [No Abstract]   [Full Text] [Related]  

  • 11. Antibiotic therapy of methicillin-resistant Staphylococcus aureus in critical care.
    Tverdek FP; Crank CW; Segreti J
    Crit Care Clin; 2008 Apr; 24(2):249-60, vii-viii. PubMed ID: 18361944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limitations of vancomycin in the management of resistant staphylococcal infections.
    Kollef MH
    Clin Infect Dis; 2007 Sep; 45 Suppl 3():S191-5. PubMed ID: 17712746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of infective endocarditis caused by methicillin-resistant Staphylococcus aureus: teicoplanin versus vancomycin in a retrospective study.
    Huang JH; Hsu RB
    Scand J Infect Dis; 2008; 40(6-7):462-7. PubMed ID: 18584532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections.
    Deresinski S
    Clin Infect Dis; 2009 Oct; 49(7):1072-9. PubMed ID: 19725789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Community associated MRSA: an alert to paediatricians.
    Jeyaratnam D; Reid C; Kearns A; Klein J
    Arch Dis Child; 2006 Jun; 91(6):511-2. PubMed ID: 16714723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vancomycin revisited: a reappraisal of clinical use.
    Cunha BA
    Crit Care Clin; 2008 Apr; 24(2):393-420, x-xi. PubMed ID: 18361953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of linezolid versus vancomycin in the treatment of methicillin-resistant Staphylococcus aureus discitis: a controlled animal model.
    Conaughty JM; Chen J; Martinez OV; Chiappetta G; Brookfield KF; Eismont FJ
    Spine (Phila Pa 1976); 2006 Oct; 31(22):E830-2. PubMed ID: 17047530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin.
    French GL
    J Antimicrob Chemother; 2006 Dec; 58(6):1107-17. PubMed ID: 17040922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
    Bennett JW; Murray CK; Holmes RL; Patterson JE; Jorgensen JH
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
    Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.